“Herpes Simplex Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Herpes Simplex Market.
The Herpes Simplex Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Herpes Simplex Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Herpes Simplex treatment therapies with a considerable amount of success over the years.
-
Herpes Simplex companies working in the treatment market are Labo'Life, AiCuris, United BioPharma, Novartis, Maruho Co., Ltd., GlaxoSmithKline, Integrative Medicine Institute, Labo'Life, Iveriapharma LLC, Agenus Inc., and others, are developing therapies for the Herpes Simplex treatment
-
Emerging Herpes Simplex therapies in the different phases of clinical trials are- Pritelivir, UB-621, famciclovir, ASP2151, GSK208141, ASP2151, Zicam (Ionic zinc), 2LHERP®, walnut extract, HerpV and QS-21, and others are expected to have a significant impact on the Herpes Simplex market in the coming years.
-
In July 2025, Assembly Biosciences has administered the first dose in the Phase Ib portion of its Phase Ia/b study, investigating ABI-1179, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor, in patients with recurrent genital herpes. This phase of the trial is designed to evaluate the safety and antiviral efficacy of weekly oral dosing over a 29-day treatment period, with antiviral activity assessed by tracking changes in HSV-2 shedding rates and HSV-2 DNA levels.
-
In April 2025, Early clinical and preclinical data shared at the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Conference in Vienna, Austria, indicate that Assembly Biosciences’ ABI-5366, a novel herpes simplex virus (HSV) helicase-primase inhibitor (HPI), has the potential to transform the treatment of recurrent genital herpes (RGH) with monthly or weekly oral dosing. Exhibiting favorable pharmacokinetics, robust tissue distribution, and nanomolar-level activity against HSV-1 and HSV-2, ABI-5366 could overcome the long-standing challenges of nucleoside analogues, particularly in terms of patient adherence and sustained response.
-
In September 2024, GSK reported that Part II of the Phase I/II TH HSV REC-003 trial for its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, failed to achieve its primary efficacy endpoint. This conclusion was based on an analysis of the primary objective data from the Phase II portion of the study. Although GSK3943104 aimed to offer a new therapeutic option for HSV, the company has decided not to progress the vaccine candidate to Phase III trials following these results.
Herpes Simplex Overview
Herpes simplex is a viral infection caused by the herpes simplex virus (HSV), commonly classified as HSV-1 (usually causing oral herpes, cold sores) and HSV-2 (usually causing genital herpes). It spreads through direct contact with infected skin or bodily fluids. Symptoms include painful blisters, itching, and sores, though some people may remain asymptomatic. There is no cure, but antiviral medications can help manage outbreaks and reduce transmission.
Get a Free Sample PDF Report to know more about Herpes Simplex Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/herpes-simplex-pipeline-insight
Emerging Herpes Simplex Drugs Under Different Phases of Clinical Development Include:
-
2LHERP®: Labo'Life
-
Pritelivir: AiCuris
-
UB-621: United BioPharma
-
famciclovir: Novartis
-
ASP2151: Maruho Co., Ltd.
-
GSK208141: GlaxoSmithKline
-
ASP2151: Maruho Co., Ltd.
-
Zicam (Ionic zinc): Integrative Medicine Institute
-
2LHERP®: Labo'Life
-
walnut extract: Iveriapharma LLC
-
HerpV and QS-21: Agenus Inc.
Herpes Simplex Route of Administration
Herpes Simplex pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Herpes Simplex Molecule Type
Herpes Simplex Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Herpes Simplex Pipeline Therapeutics Assessment
-
Herpes Simplex Assessment by Product Type
-
Herpes Simplex By Stage and Product Type
-
Herpes Simplex Assessment by Route of Administration
-
Herpes Simplex By Stage and Route of Administration
-
Herpes Simplex Assessment by Molecule Type
-
Herpes Simplex by Stage and Molecule Type
DelveInsight's Herpes Simplex Report covers around 20+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Herpes Simplex product details are provided in the report. Download the Herpes Simplex pipeline report to learn more about the emerging Herpes Simplex therapies
Some of the key companies in the Herpes Simplex Therapeutics Market include:
Key companies developing therapies for Herpes Simplex are - RedBioTec, TGV-Laboratories, Maruho, AiCuris, Sanofi, Glaxosmithkline, Starpharma, ReceptoPharm, and others.
Herpes Simplex Pipeline Analysis:
The Herpes Simplex pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Herpes Simplex with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Herpes Simplex Treatment.
-
Herpes Simplex key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Herpes Simplex Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Herpes Simplex market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Herpes Simplex drugs and therapies
Herpes Simplex Pipeline Market Drivers
-
Increasing Prevalence, Innovative Therapies, Rising Awareness, Technological Advancements, Government Support, are some of the important factors that are fueling the Herpes Simplex Market.
Herpes Simplex Pipeline Market Barriers
-
However, High R&D Costs, Regulatory Hurdles, Limited Vaccine Availability, Resistance to Current Therapies, Stigma Associated with Herpes, and other factors are creating obstacles in the Herpes Simplex Market growth.
Scope of Herpes Simplex Pipeline Drug Insight
-
Coverage: Global
-
Key Herpes Simplex Companies: Labo'Life, AiCuris, United BioPharma, Novartis, Maruho Co., Ltd., GlaxoSmithKline, Integrative Medicine Institute, Labo'Life, Iveriapharma LLC, Agenus Inc., and others
-
Key Herpes Simplex Therapies: Pritelivir, UB-621, famciclovir, ASP2151, GSK208141, ASP2151, Zicam (Ionic zinc), 2LHERP®, walnut extract, HerpV and QS-21, and others
-
Herpes Simplex Therapeutic Assessment: Herpes Simplex current marketed and Herpes Simplex emerging therapies
-
Herpes Simplex Market Dynamics: Herpes Simplex market drivers and Herpes Simplex market barriers
Request for Sample PDF Report for Herpes Simplex Pipeline Assessment and clinical trials
Table of Contents
1. Herpes Simplex Report Introduction
2. Herpes Simplex Executive Summary
3. Herpes Simplex Overview
4. Herpes Simplex- Analytical Perspective In-depth Commercial Assessment
5. Herpes Simplex Pipeline Therapeutics
6. Herpes Simplex Late Stage Products (Phase II/III)
7. Herpes Simplex Mid Stage Products (Phase II)
8. Herpes Simplex Early Stage Products (Phase I)
9. Herpes Simplex Preclinical Stage Products
10. Herpes Simplex Therapeutics Assessment
11. Herpes Simplex Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Herpes Simplex Key Companies
14. Herpes Simplex Key Products
15. Herpes Simplex Unmet Needs
16 . Herpes Simplex Market Drivers and Barriers
17. Herpes Simplex Future Perspectives and Conclusion
18. Herpes Simplex Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/